Analysis of a new doxorubicin derivative (FCE 23762) and related compounds by high performance capillary electrophoresis

High performance capillary electrophoresis was applied to analyse FCE 23762, a new anthracycline analogue (doxorubicin derivative) with anti-tumor activity. It has been shown earlier that a FCE 23762 sample may contain two main impurities, one of the optical isomers of FCE 23762 and the most probable degradation product, adriamycinone. The pharmacologically active compound and its diastereomer were resolved in free zone electrophoresis experiments. Adriamycinone, a neutral compound, is baseline separated from the other two (cationic) compounds by micellar electrokinetic chromatography. The use of two different separation methods was advantageous for an efficient and sensitive analysis for the synthetic product of FCE 23762. High performance capillary electrophoresis was applied to analyse FCE 23762, a new antracycline analogue (doxorubicin derivative) with anti-tumor activity. It has been shown earlier that a FCE 23762 sample may contain two main impurities, one of the optical isomers of FCE 23762 and the most probable degradation product, adriamycinone. The pharmacologically active compound and its diastereomer were resolved in free zone electrophoresis experiments. Adriamycinone, a neutral compound, is baseline separated from the other two (cationic) compounds by micellar electrokinetic chromatography. The use of two different separation methods was advantageous for an efficient and sensitive analysis for the synthetic product of FCE 23762